Arvinas (ARVN) Stock Price, Quote, News & History | Benzinga

Arvinas Inc (ARVN) Stock Price, Quote, News & History

ARVNNASDAQ

Trade with Public

Trade with Public

$8.40

-0.60-6.67%

At close: Aug 5, 5:00 PM EST

$8.40

N/A

After Hours: 4:44 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$8.82

Close

$8.40

Volume / Avg.

1.57M / 832.44K

Day Range

$8.21 - $8.91

52 Wk Range

6.06 - 14.51

Market Cap

$541.98M

P/E Ratio

34.54

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

7.21%

Days to Cover

6.62

Recent Arvinas Inc News

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.

Avi Kapoor

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including upgrades/downgrades, see our analyst ratings page.

Avi Kapoor

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.

Vandana Singh

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment for ESR1-mutated advanced breast cancer.

Vandana Singh

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-254.10M

Investing Cash Flow (TTM)

351.80M

Financing Cash Flow (TTM)

-91.40M

Free Cash Flow (TTM)

-256.90M

Capital Expenditure (TTM)

-2.80M

Net Change in Cash (TTM)

6.30M

Analyst Trends and Forecast

2

1

Feb

3

Mar

3

May

1

Jun

1

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$18.24M

PE Ratio (TTM)

34.54

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.91

PB Ratio (TTM)

1.03

Earnings Yield % (TTM)

2.90%

Earnings Yield % (FWD)

-44.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.71

Company Debt

Total Debt

$300.00K

LT Debt

$300.00K

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$200.00K

Total Cash

$87.30M

Debt to Equity

0.01

Issuance of Debt (TTM)

-$200.00K

Repayment of Debt (TTM)

-$200.00K

Key Statistics

Open

$8.82

Close

$8.40

Volume / Avg.

1.57M / 832.44K

Day Range

$8.21 - $8.91

52 Wk Range

6.06 - 14.51

Market Cap

$541.98M

P/E Ratio

34.54

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

7.21%

Days to Cover

6.62

About

Sector

Health Care

Industry

Pharmaceuticals

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-cau...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Arvinas (ARVN) stock?

A

You can purchase shares of Arvinas (NASDAQ:ARVN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Arvinas (ARVN) competitors?

A

There are no as such competitors for Arvinas.

Q

What is the forecast, or price target, for Arvinas (ARVN) stock?

A

Arvinas has a consensus price target of $19.92.

Q

What is the current price for Arvinas (ARVN)?

A

The stock price for Arvinas (NASDAQ: ARVN) is $8.4 last updated August 5, 2026 at 4:44 PM EDT.

Q

Does Arvinas (ARVN) pay a dividend?

A

There are no upcoming dividends for Arvinas.

Q

When is Arvinas (NASDAQ:ARVN) reporting earnings?

A

Arvinas does not have any upcoming earnings scheduled.

Q

Is Arvinas (ARVN) going to split?

A

There is no upcoming split for Arvinas.

Q

What sector and industry does Arvinas (ARVN) operate in?

A

Arvinas is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.